Market Overview

Sesen Bio Presents at AUAA Mtg., Reports Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: Biotech

 

Related Articles (SESN)

M&A Activity Prompts Argus To Upgrade Sempra Energy

The Technology Showcased At The 2018 Winter Olympics